Improving Cancer Clinical Trial Design #AACR Molecular Targets
San Francisco – the AACR-NCI-EORTC international conference on Molecular Targets and Cancer Therapeutics kicked off last Saturday with two educational sessions, including one that I attended on “Clinical Trial Paradigms in the Era of Novel Therapies.”
The session had an impressive line-up of speakers:
- New paradigms for early-phase trials (James Doroshaw)
- Phasing out phase III trials: How much evidence do we need if the target is clearly hit? (Jaap Verweij)
- Development of clinical trials incorporating genomic signatures: Lessons learned? (Lisa McShane)
- Clinical trial designs for targeted therapies (John Crowley)
The recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference in San Francisco was an informative meeting.